Company profile
Ticker
BOLD
Exchange
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
830751369
BOLD stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
2 Apr 24
S-8
Registration of securities for employees
28 Mar 24
424B4
Prospectus supplement with pricing info
28 Mar 24
EFFECT
Notice of effectiveness
28 Mar 24
CERT
Certification of approval for exchange listing
27 Mar 24
8-A12B
Registration of securities on exchange
22 Mar 24
S-1/A
IPO registration (amended)
21 Mar 24
S-1
IPO registration
6 Mar 24
DRS/A
Draft registration statement (amended)
23 Jan 24
DRS/A
Draft registration statement (amended)
11 Oct 23
Latest ownership filings
SC 13G
RA CAPITAL MANAGEMENT, L.P.
12 Apr 24
SC 13G
Nextech VI GP S.A.R.L.
12 Apr 24
SC 13G
FMR LLC
10 Apr 24
SC 13G
BAYER HEALTHCARE LLC
9 Apr 24
4
Kristina Burow
4 Apr 24
4
Jonathan E Lim
4 Apr 24
4
KEITH CRANDELL
4 Apr 24
4
Change in insider ownership
4 Apr 24
4
Rajeev M. Shah
4 Apr 24
4
Change in insider ownership
2 Apr 24
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Wellington Biomedical Innovation Master Investors | Common Stock | Conversion | Acquire C | No | No | 0 | 366,300 | 0.00 | 556,233 |
2 Apr 24 | Wellington Biomedical Innovation Master Investors | Common Stock | Conversion | Acquire C | No | No | 0 | 189,933 | 0.00 | 189,933 |
2 Apr 24 | Wellington Biomedical Innovation Master Investors | Series C Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 7,142,857 | 0.00 | 0 |
2 Apr 24 | Wellington Biomedical Innovation Master Investors | Series B Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 3,703,704 | 0.00 | 0 |
2 Apr 24 | Ra Capital Management | Common Stock | Buy | Acquire P | Yes | No | 16 | 15,625 | 250.00 k | 295,844 |
2 Apr 24 | Ra Capital Management | Common Stock | Conversion | Acquire C | Yes | No | 0 | 280,219 | 0.00 | 280,219 |
2 Apr 24 | Ra Capital Management | Common Stock | Buy | Acquire P | Yes | No | 16 | 296,875 | 4.75 mm | 1,884,787 |
2 Apr 24 | Ra Capital Management | Common Stock | Conversion | Acquire C | Yes | No | 0 | 1,587,912 | 0.00 | 1,587,912 |
2 Apr 24 | Ra Capital Management | Series C Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 2,464,286 | 0.00 | 0 |
2 Apr 24 | Ra Capital Management | Series C Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 13,964,285 | 0.00 | 0 |
News
Leerink Partners Initiates Coverage On Boundless Bio with Outperform Rating, Announces Price Target of $25
22 Apr 24
Guggenheim Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $24
22 Apr 24
Piper Sandler Initiates Coverage On Boundless Bio with Overweight Rating, Announces Price Target of $20
22 Apr 24
Boundless Bio Presents Preclinical And Clinical Pharmacodynamic Data On Lead ecDNA-Directed Therapy, BBI-355, At AACR Annual Meeting 2024
8 Apr 24
Reported Earlier, Boundless Bio Prices Initial Public Offering Of 6.25M Common Shares At $16/Share
28 Mar 24
Press releases
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
11 Apr 24
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
8 Apr 24
Boundless Bio Announces Pricing of Initial Public Offering
27 Mar 24